Meticel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meticel

What is Meticel? Overview

Property Description
Active Ingredient Celecoxib
Form Capsule (Oral Dosage Form)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Specific Subclass Cyclooxygenase-2 (COX-2) Selective Inhibitor
Origin Synthetic Compound

Meticel is a prescription-only medicine whose active component is the single-ingredient substance Celecoxib, which is fundamentally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It belongs to the specific, modern pharmacological class known as a Cyclooxygenase-2 (COX-2) selective inhibitor. The Meticel brand provides the active ingredient Celecoxib in a simple, oral capsule formulation for systemic use in adults.

The compound, Celecoxib, is a synthetic entity used in managing symptoms of pain and inflammation. As a COX-2 selective inhibitor, it is designed to reduce the risk of serious gastrointestinal issues compared to some older NSAIDs. This means the medicine is created to relieve discomfort with a specific focus on the body’s inflammatory response, while being mindful of other bodily processes.

Composition, Form, and General Purpose

Meticel is prepared as a single-ingredient product and is presented as an oral capsule for convenient administration. The formulation is intended for adults seeking relief from conditions characterized by inflammation. The general purpose of Meticel, based on its selective mechanism, is to provide targeted relief from pain and swelling by reducing the body's inflammatory response.

Celecoxib exerts its therapeutic effects by selectively inhibiting the COX-2 enzyme. This targeted mechanism allows the medication to interrupt the process that signals pain and swelling throughout the body. A typical neutral use scenario involves relieving discomfort associated with chronic inflammation, thereby improving mobility and quality of life.

What side effects are possible with Meticel?

Possible Side Effects and Safety Information

The official safety profile for Meticel (Celecoxib) is categorized by regulatory bodies to describe potential adverse reactions and safety constraints. As a Cyclooxygenase-2 (COX-2) selective NSAID, the medication carries warnings regarding serious risks that are formally documented in prescribing information, such as the FDA's Boxed Warning.

Documented Adverse Reactions and Risks

Classification Description
Common Side Effects Adverse reactions reported as common include flatulence, dyspepsia, diarrhea, abdominal pain, peripheral edema (swelling), headache, and upper respiratory tract infection.
Serious Adverse Reactions The label highlights the potential for serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal events (including bleeding, ulceration, and perforation). Severe skin reactions (e.g., Stevens-Johnson Syndrome) and hepatotoxicity (severe liver injury) are also documented.
Time-Related Patterns The risk of serious cardiovascular and gastrointestinal events may increase with dose and duration of use, with serious GI events being more frequently observed with long-term exposure.

Regulatory Safety Constraints

The medicine is subject to specific safety limitations defined in regulatory documents. Contraindications include a known sulfonamide allergy or allergic reactions to other NSAIDs, and its use is restricted in patients undergoing Coronary Artery Bypass Graft (CABG) surgery. Use is also cautioned or avoided in cases of severe hepatic or renal impairment. Specific safety statements apply to older adults, who have an increased risk for serious gastrointestinal complications, and use is restricted during late pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the required actions and clinical manifestations in the event of an overdose involving Meticel (celecoxib). Management of overdose is limited to symptomatic and supportive care, as no specific antidote is known for this medication.


Documented Overdose Presentations and Severe Outcomes

Regulatory information states that symptoms following an acute overdose may include lethargy, drowsiness, nausea, vomiting, and epigastric pain. While these symptoms are generally reversible with supportive care, overdose has the potential to escalate to severe or life-threatening systemic outcomes.

  • Severe Manifestations may include gastrointestinal bleeding, acute renal failure, hypertension, respiratory depression, and coma.

Mandatory Emergency Actions

The official labeling provides clear instructions on when urgent medical assistance is required.

Action Required When to Seek Urgent Help
Seek emergency medical attention Immediately following a suspected or actual overdose.
Contact a poison control center or emergency room At once, even if no symptoms are present.

Procedural steps, such as administering activated charcoal and/or an osmotic cathartic, may be considered by medical professionals for patients presenting within four hours of ingestion. Due to the drug's high plasma protein binding, regulatory sources indicate that dialysis is unlikely to be useful for drug removal.

Therapeutic Uses of Meticel

Meticel (Celecoxib) is commonly applied in addressing symptomatic management across several major therapeutic domains, which may assist with easing patient discomfort and support functional stability. It is considered relevant in conditions presenting with systemic or localized discomfort.

The medication is relevant for managing symptom clusters related to chronic conditions affecting the joints and spine, which may require long-term symptomatic support. This includes conditions such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), and Juvenile Rheumatoid Arthritis (JRA). It is also applied in acute therapeutic contexts, including Primary Dysmenorrhea (menstrual cramps) and pain following medical procedures.

“The medication helps address symptom clusters that may become intense or disruptive, providing support to help ease the overall symptom burden.”

The core benefit contributes to improved day-to-day comfort and assists with maintaining functional stability during periods where symptoms may interfere with routine activities. For highly specialized cases, Meticel may also be part of symptomatic management as an adjunctive measure in clinical settings for patients diagnosed with Familial Adenomatous Polyposis (FAP).

Quick Fact: Relevant for Joint Stiffness and Pain

Regulatory References

  1. NIH DailyMed official label information

Eligibility and Restrictions for Use

Eligibility for Meticel

Official regulatory documents define strict criteria for who can and cannot use Meticel (Celecoxib). The drug is permitted for adults for all labeled conditions and for pediatric patients 2 years of age and older for Juvenile Rheumatoid Arthritis (JRA). Use in children under 2 years is not established.

Category Regulatory Status
Immunological Contraindicated in patients with a known sulfonamide allergy or history of allergic reactions to aspirin or other NSAIDs (e.g., asthma, urticaria).
Surgical/Cardiac Contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery. Caution required for patients with pre-existing cardiovascular risk factors.
Severe Organ Impairment Prohibited in severe hepatic impairment (Child-Pugh Class C) and advanced renal disease (creatinine clearance <30 mL/min).
Pregnancy/Lactation Contraindicated starting at 30 weeks gestation. Generally not recommended during lactation.

Eligibility is further restricted for those with moderate hepatic impairment or who are known CYP2C9 poor metabolizers, often requiring cautious use. The elderly are advised to use the medicine with caution due to increased risk of serious gastrointestinal and renal events.

What should I know about interactions with other medicines?

Meticel Interactions with other medicines and products

Official regulatory information describes several clinically significant interaction patterns for Meticel (Celecoxib), a COX-2 selective NSAID, focusing on altered plasma exposure and increased pharmacological risk.

Interaction Classifications (High-Level)

Classification Details / Context
Interaction Severity Use is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery. Significant interactions occur with drugs that inhibit CYP2C9 metabolism.
Interaction Context The risk of deterioration of renal function is heightened when co-administered with ACE Inhibitors or ARBs in elderly or volume-depleted patients.

Official Interaction Statements

  • Pharmacokinetic Interactions: Co-administration with the strong CYP2C9 inhibitor Fluconazole significantly increases celecoxib plasma levels (AUC) due to reduced metabolic clearance.
  • Pharmacodynamic Interactions: Concurrent use with warfarin or other coumarin-type anticoagulants increases the documented risk of serious bleeding events.
  • Exposure-Modifying Substances: Meticel can cause elevations in plasma concentrations of Lithium by reducing its renal clearance, which may lead to toxicity. The product may also increase the serum concentration of Digoxin.
  • Antihypertensive Agents: Co-administration with agents such as ACE Inhibitors or Diuretics may diminish the antihypertensive effect of these medications.
  • Non-Medicinal Interactions: The consumption of alcohol with Meticel increases the risk of serious gastrointestinal problems.

The official interaction profile is structured around defined pharmacokinetic alterations via the CYP2C9 enzyme and specific pharmacodynamic effects, such as the additive risk of bleeding with anticoagulants. This regulatory framework outlines combinations that are formally prohibited, such as use following CABG surgery, and those requiring careful consideration due to altered drug concentrations or amplified risk profiles.

Mechanism of Action

Selective Inhibition of Prostaglandin Production

Meticel functions as a selective inhibitor of the Cyclooxygenase-2 (COX-2) enzyme, which is responsible for the synthesis of pro-inflammatory mediators, primarily Prostaglandin E2 ( PGE2), at sites of cellular stress or injury. By acting as a competitive inhibitor, the molecule suppresses this key step in the eicosanoid biosynthesis pathway, thereby decreasing the local and systemic concentrations of these signaling molecules.

Modulation of Nociceptive and Thermoregulatory Signaling

The reduction in PGE2 concentration leads directly to two physiological effects. Peripherally, it reduces the sensitization of nociceptors (pain-sensing neurons) and alters ascending signaling patterns. Centrally, the inhibition of PGE2 synthesis within the hypothalamus allows the body's thermoregulatory set-point to normalize, which contributes to the dissipation of an elevated body temperature.

Preservation of Homeostatic Physiological Functions

The mechanism is characterized by a high degree of selectivity for COX-2, which results in minimal interference with the functions of the COX-1 enzyme. This preservation of COX-1 activity allows for the continued production of constitutive Prostaglandins that are necessary for maintaining homeostatic functions, such as those involved in gastric mucosal maintenance.

Dosage and Administration Information

Official Administration Instructions for Mexiletine

This section outlines the administration protocol for Mexiletine (Meticel) capsules used in the treatment of ventricular arrhythmias.

Administration Scope

  • Route of Administration: Oral (Capsule).
  • Timing in Relation to Meals: The capsule must be taken with food or an antacid to help prevent stomach upset.
  • Preparation Requirements: No special preparation (e.g., dilution, shaking) is required for the capsule formulation.

Dosing Schedule and Procedure

The dosage is highly individualized and is determined by a healthcare professional based on the patient’s response and tolerance.

Dosing Parameter Official Regulatory Guidance
Initial Dose (Standard) 200 mg every eight hours (q8h).
Loading Dose (Rapid Control) 400 mg initially, followed by 200 mg in eight hours.
Maintenance Range Typically 200 mg to 300 mg q8h; not to exceed a maximum of 1200 mg per day.
Dose Adjustment Incremental changes of 50 mg or 100 mg should be made no more often than every two to three days.

Special Conditions

  • Age-Group Rules: Dosage for adults is specified above. Use and dose in children must be determined by the prescribing physician.
  • Missed-Dose Rules: If a dose is missed, take it as soon as it is remembered. If it is nearly time for the next scheduled dose, skip the missed dose and continue the regular schedule. Do not take a double dose.
  • Transfer Protocol: When transitioning from another oral Class I antiarrhythmic agent, Mexiletine may be initiated 6 to 12 hours after the last dose of the previous agent.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Meticel (Celecoxib)

Meticel was studied in clinical trials that explored patterns of symptoms related to chronic pain and inflammation, as well as acute episodes of discomfort. The available evidence, largely consisting of randomized controlled trials (RCTs) and systematic reviews, describes patterns of patient-reported changes in symptoms and functional status. Findings describe group patterns and do not determine how an individual may respond.


Evidence for Chronic Joint and Spinal Conditions

Evidence for Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

Researchers have conducted numerous short-term and intermediate-term Randomized Controlled Trials (RCTs) and large-scale meta-analyses to explore Meticel in conditions marked by functional limitations and joint pain. These studies monitored adult patients, including older adults. The primary outcomes examined included measurements of patient-reported pain intensity and functional outcomes or activity level. Studies reported on how symptoms evolved in the observed populations, describing patterns of patient-reported change in pain scores and stiffness assessments in the joints.

Evidence for Ankylosing Spondylitis (AS)

Research on Meticel for conditions involving periods of heightened symptom activity, such as Ankylosing Spondylitis, primarily involves Randomized Controlled Trials (RCTs). These studies monitored specific outcomes related to functional imbalance, such as changes in spinal mobility and functional limitation indices. Trial data show patterns related to patient-reported changes in pain and functional scales during the observed time intervals.


Research Evidence for Acute Pain and Specialized Uses

Studies for Acute Pain and Primary Dysmenorrhea

For conditions characterized by fluctuating or episodic manifestations, such as acute pain and menstrual cramps (primary dysmenorrhea), research explored short-term symptom changes. Studies used randomized, controlled designs to measure analgesic efficacy and the time-weighted reduction in pain intensity. The trials reported measurements of pain relief, describing patterns of pain score modification during the acute, short-term use period.

Evidence for Familial Adenomatous Polyposis (FAP)

Meticel was also evaluated in research as an adjunctive measure in studies exploring Familial Adenomatous Polyposis (FAP). Research specifically examined the number and size of polyps in the colorectal area of patients. The research focusing on polyp number did not assess the long-term risk of developing intestinal cancer or the need for surgery. The data are limited to describing the changes in polyp characteristics alone.


What is Still Uncertain About the Research for Meticel

Long-term effects related to sustained symptomatic change over a decade or more are not fully established. Data for certain groups remain insufficient, particularly for patients with a high burden of other conditions. Research does not determine whether an individual will respond similarly to the group patterns described in the trials. The results apply only to the populations studied and the specific conditions under which the research was conducted.

Key Studies & References

  1. CELECOXIB 200 MG - celecoxib capsule, Label (FDA/DailyMed)
  2. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials - NCBI
  3. Study Details | NCT00005094 | Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps | ClinicalTrials.gov (FAP Trial)
  4. Top-Line Data Show Celecoxib Met Primary Objective In Clinical Trial To Evaluate The Effects On Blood Pressure In Pediatric Patients With Juvenile Idiopathic Arthritis | Pfizer (JRA Study)

Frequently Asked Questions (FAQ)

Common questions about Meticel (FAQ)

Q: How long do the effects of Meticel usually last?

Meticel is absorbed rapidly after a dose. Official pharmacokinetic information describes that the drug typically reaches its highest level in the bloodstream, or peak plasma levels, within approximately three hours. The time documented for half of the drug to leave the body is around 11.2 hours.

Q: Can taking Meticel affect my ability to drive or operate machinery?

Regulatory documents advise caution for individuals using Meticel. If a patient experiences certain effects, such as dizziness, vertigo (a spinning sensation), or somnolence (drowsiness), official documents advise refraining from driving or operating complex machinery until these effects have passed.

Q: What happens when Meticel interacts with alcohol?

Official regulatory warnings state that combining Meticel with alcohol increases the risk of serious gastrointestinal issues. This includes potential complications like bleeding or ulceration in the stomach or intestines.

Q: Can Meticel be taken with common over-the-counter pain relievers like ibuprofen?

Regulatory documents caution that combining Meticel with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen, increases the documented risk of certain adverse effects, such as gastrointestinal bleeding. Meticel should not be used with these medications.

Q: Does Meticel affect the effectiveness of birth control pills?

Official regulatory documents list several medications that interact with Meticel, such as warfarin and lithium. However, the product's formal interaction tables do not contain a specific statement confirming or denying an effect on hormonal contraceptives (birth control pills).

Q: Can Meticel cause weight changes?

The safety information for Meticel lists fluid retention, also known as peripheral edema (swelling), as a possible side effect. In some serious cases, fluid retention is associated with heart failure and may include sudden weight gain. General weight loss or gain is not listed as a common side effect.

Q: Is Meticel the same kind of medicine as [similar drug name]? (high-level)

Meticel is classified as a COX-2 selective Nonsteroidal Anti-inflammatory Drug (NSAID). Official descriptions highlight its selective mechanism, which is described as having a specific focus on mitigating serious gastrointestinal issues compared to some non-selective NSAIDs.

Q: How quickly does Meticel typically start to work after the first use?

The drug is typically absorbed quickly. According to pharmacokinetic studies, the highest concentrations in the bloodstream are generally reached about three hours after a patient takes the capsule.

Q: Are there any common reasons why Meticel might not work for someone?

Official documents note that a small number of people are considered 'poor metabolizers' for the specific liver enzyme that processes Meticel. This can lead to unusually high drug levels. Beyond this, the documents do not list common, specific reasons for a lack of treatment response, as the findings describe group patterns and not individual outcomes.

Q: Is Meticel considered a controlled substance?

No. Official regulatory information indicates that Meticel, whose active ingredient is Celecoxib, is not classified as a controlled substance under the federal Controlled Substances Act (CSA).

Q: Can people with liver issues use Meticel?

Official eligibility documents prohibit the use of Meticel in patients with severe hepatic impairment (Child-Pugh Class C). For moderate hepatic impairment, regulatory guidance generally recommends that the dose be adjusted.

Q: Has Meticel been studied in children or adolescents?

Yes, Meticel is specifically approved and indicated for the treatment of Juvenile Rheumatoid Arthritis (JRA) in pediatric patients who are 2 years of age and older. Its use is not established in children younger than 2 years of age.

Q: Is Meticel a drug that needs to be used for a long time?

Regulatory agencies advise that Meticel, like all drugs in its class, should be used for the shortest duration possible. Warnings state that the risk of serious side effects, particularly those affecting the heart and digestive system, may increase with both the size of the dose and the length of time the medicine is used.

Q: Is the name Meticel the brand name or the generic name?

Meticel is the brand name of the medicine. The active ingredient contained within the capsule is Celecoxib, which is the official generic name.

Q: Why did the regulatory agency approve Meticel?

The regulatory decision was based on evidence indicating that its selective mechanism was associated with an intended reduction in the risk of serious gastrointestinal issues compared to some older, non-selective NSAIDs. Meticel was approved to manage symptoms of pain and inflammation.

Q: What is the intended duration of use for Meticel?

The medication is intended for use at the lowest effective dose for the shortest duration possible. For acute, short-lived pain, Meticel is typically indicated for short-term management, often specified as up to seven days.

Q: How is the safety of Meticel monitored after it is released to the public?

The safety of Meticel is subject to ongoing post-marketing surveillance by regulatory agencies. This includes periodic safety reviews (pharmacovigilance) where adverse events reported by patients and doctors are collected and analyzed to monitor and assess the drug's continuing risk-benefit profile.

Q: Can Meticel be used for things other than its main approved use?

Regulatory documents specify a list of conditions for which Meticel is formally indicated and approved. The medicine is not indicated for any uses or conditions outside of those formally approved and specified in the official prescribing information.

Q: Why do official documents mention 'unknown risk' for Meticel in certain populations?

Official documents note that data for certain groups (e.g., long-term effects, high-risk patients) remain insufficient, which leads to regulatory warnings about unknown or unestablished risks in those populations. This is a common practice when evidence is limited.

Q: Does Meticel contain any common allergens like lactose or gluten?

Meticel contains the inactive ingredient lactose monohydrate. Due to this component, official warnings caution against use in patients with rare hereditary problems like galactose intolerance. The documentation does not typically list the presence of gluten.

Q: Is Meticel known to interact with caffeine?

While caffeine is not listed in the main interaction tables, some authoritative sources indicate that combining Meticel with caffeine may increase the chance of gastrointestinal irritation, similar to the warning documented for alcohol consumption.

Q: Can Meticel affect blood sugar levels?

Regulatory information advises patients who have diabetes mellitus (a condition related to blood sugar control) to use Meticel with caution. This caution indicates that the medicine requires special consideration in this population.

How should Meticel be stored and disposed of?

How to Store and Dispose of Meticel?

Official regulatory documents define strict requirements for storing and disposing of Meticel (Methylcellulose) to maintain product quality and safety.


Storage and Handling Requirements

Classification Requirement
Temperature Control Store the product below the maximum temperature specified by the manufacturer (e.g., below 25 C or 30 C).
Stability Constraint Do not freeze the product to prevent damage to the formulation.
Child Safety Keep this medicine out of the sight and reach of children to prevent unintentional exposure.
In-Use Stability If applicable (e.g., eye drops), the product must be discarded after the documented period following first opening.

Official Disposal Rules

Unused or expired Meticel should be handled according to public health guidelines. Priority is given to drug take-back programs or mail-back schemes. If such programs are unavailable, the medicine should be mixed with an unappealing substance (like used coffee grounds) and placed in a sealed container in the household trash. It is generally advised not to flush the product down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meticel found in:

A-Z Index: